source
- Zenidatamab regimens show survival benefit in HER2-positive gastric cancer, but PD-L1 test variability raises treatment questionsThe HERIZON‑GEA‑01 study reports that zenidatamab‑based treatment schedules lead to a notable improvement in overall survival for patients with HER2‑positive gastric cancer. These efficacy finding…
- CREATE Medicines raises $122 million to advance CAR-T candidates into human trialsCREATE Medicines, formerly Myeloid Therapeutics, announced a $122 million financing round. The funding came from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners and other invest…